Open
The Marked Chart Wire · Health
Wegovy
Novo Nordisk presented real-world results showing that semaglutide 2.4 mg improved liver markers, body weight, and glucose levels in adults with MASH. The drug outperformed resmetirom in reducing AST and other cardiometabolic indicators.
Prices from Live · updated 3:55 PM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
Measles
American health officials report over 5,000 confirmed measles cases, the most recorded in three and a half decades.
Cognition
Cognition outlined a plan to begin Phase III trials for DLB in mid-2027. The company stated it has sufficient cash to operate through the fourth quarter of 2027.
Arcturus
Arcturus intends to initiate Phase II testing of its ARCT-2601 drug candidate next quarter. The company anticipates releasing preliminary results in the second half of 2027, following a 38-fold improvement in potency for the LUNAR 2.0 program.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.